Markets:

Overview

News

Currencies

International

Treasuries

Novo Nordisk A/S Common Stock (NY:NVO)

47.42 -1.03 (-2.13%)

Official Closing Price Updated: 7:00 PM EST, Feb 20, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Novo Nordisk A/S Common Stock

< Previous 1 2

...

30 31 32 33 34 35 36 37 38

...

99 100 Next >

NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) – A Strong Candidate for Value Investors ↗

May 28, 2025

NOVO-NORDISK (NYSE:NVO) offers strong profitability, solid growth, and reasonable valuation, making it a compelling choice for value investors. Its financial health and industry-leading margins add...

Via Chartmill

Novo Nordisk's 52% Plunge: Is the Company Fumbling Its Leadership in the $150 Billion Weight Loss Market? ↗

May 28, 2025

Ozempic helped Novo Nordisk gain an early lead in the weight loss industry, but competition is nipping at the company's heels.

Via The Motley Fool

10 Health Care Stocks Whale Activity In Today's Session ↗

May 27, 2025

Via Benzinga

3 Surprising Stocks That Have More Than Doubled in 2025 ↗

May 27, 2025

Just 14 stocks with market caps above $1 billion have doubled so far this year. They probably aren't the winners you would have predicted.

Via The Motley Fool

Topics Government

Why Novo Nordisk Stock Just Popped ↗

May 27, 2025

President Trump has good news for Novo Nordisk investors, and more may be on the way.

Via The Motley Fool

Topics Government World Trade

"If Walmart Is Under Pressure to Raise Prices, It's Going to Have Broader Effects on the Economy." ↗

May 27, 2025

Via The Motley Fool

Topics Earnings Economy World Trade

8 Health Care Stocks With Whale Alerts In Today's Session ↗

May 23, 2025

Via Benzinga

Analysts Think These Stocks Could More Than Double in Value

May 23, 2025

Septerna, Intellia, and Novavax have garnered investor attention for their significant upside potential, but investors should beware the risks as well.

Via MarketBeat

Topics World Trade

Hims & Hers Stock Drops After Evernorth Announces Cheaper Pricing For Weight-Loss Drugs: Retail’s Dull ↗

May 22, 2025

Truist noted on Thursday that the $200/month price point is "highly attractive compared to other price points in the market," including Hims & Hers' compounded Semaglutide, Wegovy, and Liraglutide...

Via Stocktwits

Novo Nordisk To Sell Wegovy For $199 A Month As Compounding Ban Nears: Retail’s Bullish ↗

May 22, 2025

The offer will be valid through June 30 and aims to encourage patients who previously used compounded versions of the drug to move to Wegovy.

Via Stocktwits

Did Eli Lilly Just Say Checkmate to Novo Nordisk? ↗

May 22, 2025

Via The Motley Fool

Wegovy, Zepbound Just Got Cheaper: Cigna Sets $200 Monthly Limit For Weight-Loss Drug Users ↗

May 22, 2025

Cigna’s Evernorth has reached agreements with Eli Lilly and Novo Nordisk to reduce prices for GLP-1 weight-loss drugs Wegovy and Zepbound

Via Stocktwits

Best Healthcare Stocks: Eli Lilly vs. Novo Nordisk ↗

May 21, 2025

Via The Motley Fool

10 Health Care Stocks With Whale Alerts In Today's Session ↗

May 20, 2025

Via Benzinga

Why Novo Nordisk Stock Popped on Tuesday ↗

May 20, 2025

If you can't beat Novo Nordisk, maybe you should join 'em?

Via The Motley Fool

2 Fantastic Beaten-Down Growth Stocks Down 40% and 45% to Buy ↗

May 20, 2025

These two stocks are poised for near-term and long-term upside.

Via The Motley Fool

The End Of The Diabetes Industry? This Small Cap Could Upend The Business Models of Pharma Giants ↗

May 19, 2025

is it the end of the diabetes industry? Here's a small cap that could upend the business models of pharma giants...

Via Benzinga

MarketBeat Week in Review – 05/12 - 05/16

May 17, 2025

Stocks had a strong week on a potential U.S.-China trade deal and cooler inflation data, but volatility may remain as investors shift focus to tax cuts

Via MarketBeat

Topics Artificial Intelligence Economy Government

NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) – A Strong Growth Stock with Technical Breakout Potential ↗

May 17, 2025

NOVO-NORDISK (NYSE:NVO) is a strong growth stock with solid fundamentals and a promising technical setup, offering potential for a breakout.

Via Chartmill

On Holding on Fire ↗

May 17, 2025

A consumer goods company hit 40% yearly revenue growth. In this environment?

Via The Motley Fool

Topics Bonds Government

3 Stocks That Will Profit From Trump's Drug Price Cut ↗

May 16, 2025

Trump's EO aims to lower US drug prices by using leverage of public programs (like Medicare) to force accountability. Big pharma may be hit hardest.

Via Benzinga

Topics Government

Why Novo Nordisk Stock Just Slipped ↗

May 16, 2025

Investors may get a second bite at the apple, and a second chance to buy this GLP-1 drug leader at a discount price.

Via The Motley Fool

Novo Nordisk Sheds 4% After Ousting CEO As Eli Lilly Rivalry Slams Stock Price ↗

May 16, 2025

Novo Nordisk said Friday it will replace its CEO, citing a sharp tumble for Novo shares amid growing competition.

Via Investor's Business Daily

Ozempic Maker Novo Nordisk Looks For New Chief, Jørgensen Steps Down From CEO Role ↗

May 16, 2025

Novo Nordisk CEO steps down after pressure from shareholders. Former CEO to join board as observer. Company remains optimistic amid mixed signals.

Via Benzinga

Novo Nordisk CEO Lars Jørgensen Steps Down Amid Challenges, Retail Chatter Spikes ↗

May 16, 2025

The company said it would announce the next CEO in “due course,” but did not provide a more definite timeline.

Via Stocktwits

Wall Street Expects This Obesity Drug Stock to Skyrocket 35% Over the Next 12 Months ↗

May 16, 2025

Via The Motley Fool

Is It Time to Buy the Dip in Novo Nordisk Stock?

May 15, 2025

Novo Nordisk stock is down nearly 50% in 2025 as competition in the GLP-1 space continues to mount, but the fundamental case for the NVO stock is growing

Via MarketBeat

Topics Government

Novo Nordisk's Ozempic Weight Loss Jabs Could Boost UK Economy By $6 Billion, Study Finds ↗

May 14, 2025

Weight loss drugs like semaglutide could add £4.5 billion to the UK economy annually, boosting productivity and reducing alcohol use, though high costs may limit broad access.

Via Benzinga

Topics Economy

Novo Nordisk Inks $2.2 Billion Deal With Septerna To Develop Oral Weight Loss And Diabetes Drugs ↗

May 14, 2025

Novo Nordisk and Septerna enter $2.2 billion deal to develop oral small-molecule therapies targeting obesity, diabetes, and cardiometabolic diseases.

Via Benzinga

Novo Nordisk Inks A Major Obesity Deal, Sending Shares Of New Partner Septerna Skyrocketing ↗

May 14, 2025

The deal is worth up to $2.2 billion, including more than $200 million in upfront and near-term payments.

Via Investor's Business Daily

< Previous 1 2

...

30 31 32 33 34 35 36 37 38

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Novo Nordisk A/S Common Stock (NY:NVO)

All News about Novo Nordisk A/S Common Stock

Starting at $3.75/week.

Subscribe Today